Maroun Richard E 4

What Happened

• Richard E. Maroun, a director of Whitehawk Therapeutics, received a grant of 38,040 derivative securities on June 12, 2026. The transaction is reported as an acquisition (code A) at $0.00 per share (no purchase price shown). The instrument is described in the filing as an option (see footnote) rather than a market purchase or sale.

Key Details

• Transaction date: June 12, 2026; Form 4 filed June 15, 2026 (filed within the normal 2-business-day window).
• Reported terms: 38,040 derivative shares/options; price reported $0.00 per share on the Form 4.
• Vesting (footnote F1): 100% of the option vests on the earlier of (i) one-year anniversary of the grant (June 12, 2027) or (ii) the day before the next annual meeting, contingent on the reporting person remaining a service provider.
• Shares owned after transaction: not specified in the provided filing summary.
• Transaction type: Award/grant of derivative securities (not a sale or open-market purchase).

Context

• This is a compensation-related option grant to a director, subject to a cliff vesting condition tied to continued service; it does not represent an immediate cash sale or purchase in the market. Such awards are common for board members and are primarily a retention/compensation mechanism rather than a direct signal of buying or selling intent.